Why LDL Can Stay High Anyway

The overlooked physiology behind stubborn cholesterol numbers despite good habits

You can eat well, lose weight, and still have an LDL that refuses to cooperate.

That does not always mean you are doing something wrong. Often, it means the real driver is not diet at all, but something deeper in the way your body is processing cholesterol.

[I also walk through this step-by-step here (video)]

What This Really Means

Many people are told, directly or indirectly, that high LDL mainly reflects poor food choices. That is only part of the story. LDL is shaped not just by what you eat, but by how your liver clears cholesterol, how your hormones regulate metabolism, whether insulin resistance is developing, whether kidney disease is present, and even whether the lab was drawn during a period of rapid weight loss. Untreated hypothyroidism can reduce LDL receptor activity and worsen clearance, nephrotic syndrome can raise LDL through both overproduction and reduced catabolism, and normal pregnancy and menopause can both shift lipids in predictable ways.

My Clinical Framework on Secondary Causes of High LDL

1. Ask whether the number fits the person.
   If someone is eating reasonably well and the LDL still seems out of proportion, I start thinking about secondary causes before assuming nonadherence.

2. Look upstream metabolically.
   A fasting insulin can sometimes reveal insulin resistance before A1C becomes clearly abnormal. That matters because insulin resistance often shifts lipoproteins in a more atherogenic (artery clogging) direction even before diabetes is diagnosed.

3. Check whether timing is distorting the result.
   During major weight loss, cholesterol can temporarily rise as adipose cholesterol is mobilized. In practice, I am more cautious interpreting LDL while weight is still moving.

4. Audit the medication list carefully.
   Glucocorticoids can worsen lipid profiles, and thiazide diuretics can sometimes raise LDL and triglycerides, especially at higher doses. Some psychiatric medications raise risk more indirectly through weight gain and insulin resistance than through a direct LDL effect.

What I’d Do If This Were Me or My Family

I would not assume I had simply failed at diet. I would want one careful step back before taking one aggressive step forward.

For myself or someone I love, I would want to know whether the number reflects thyroid disease, kidney protein loss, insulin resistance, menopause, medication effects, or a transient state like recent illness or active weight loss. The uncertainty matters because the right next step is not always “more restriction.” Sometimes it is better timing, better testing, or better clinical context.

Key Numbers That Matter

• Pregnancy: LDL often rises about 30 to 50% in normal pregnancy.

• Postmenopause: Early postmenopausal women have about 2.1 times the odds of LDL-C at least 130 mg/dL versus premenopausal women.

• Prednisolone: Clinical studies associate it with higher LDL and total cholesterol than hydrocortisone replacement.

• Hydrochlorothiazide: Higher doses can cause a temporary rise in LDL and triglycerides.

Biggest Mistake I See Patients Make

The biggest mistake is treating LDL as a moral scorecard.

Once people think the number is simply a verdict on discipline, they often miss the more useful question: what is the body doing that explains this result? That mindset shift is often where better care begins.

Who This Applies To (and Who It Doesn’t)

Applies to:

• People with persistently high LDL despite a fairly thoughtful diet

• Patients with central weight gain, prediabetes, diabetes, or suspected insulin resistance

• Women who notice a change during pregnancy, perimenopause, or after menopause

May not apply to:

• People with clearly established familial hypercholesterolemia, where the main issue is inherited LDL clearance impairment

• Situations where LDL is already well controlled and the question is primarily treatment maintenance

A Test Worth Discussing With Your Doctor

Fasting insulin!

It is not the right test for every situation, but it can sometimes reveal an earlier metabolic problem than A1C or fasting glucose alone. In the person whose LDL seems strangely high for the lifestyle, that added context can be surprisingly useful.

If You Only Remember One Thing, Remember This

High LDL is a clue, not a complete explanation.

My Take / My Bias

My bias is toward interpretation before escalation. If the number and the story do not match, I usually think the next job is to understand the physiology more clearly, not just intensify blame or treatment reflexively. LDL matters, but context matters too.

If you’d like to see how I walk through this step-by-step:

Closing

Thank you for reading. High LDL can be discouraging precisely because it looks simple on paper and often is not simple in the body. If this clarified the issue for you, or for someone you care about, feel free to pass it along.

Paid subscribers are always welcome to leave thoughtful questions or comments below.

To your health,
-Dr. Haque

P.S. What I’m Reading This Week

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes.
A new BMJ cohort study examined whether GLP-1 receptor agonists were associated with lower risks of substance use disorders among U.S. veterans with type 2 diabetes.
Why it matters: It is an intriguing example of how drugs developed for metabolism may have effects that reach into behavior and addiction medicine, though this was observational research and not proof of causation.

Development of the Weight and Emotions Scale (WES).
This paper describes a new patient-reported outcome measure designed to assess the emotional impact of obesity more rigorously in research and clinical studies.
Why it matters: Good obesity care is not only about pounds or A1C. Better measurement of emotional burden may improve how trials and clinicians understand the lived experience of obesity.

The New York Times report on electronic fetal monitoring and C-sections.
The article examines how continuous electronic fetal monitoring may contribute to unnecessary C-sections despite decades of concern about limited benefit in low-risk labor.
Why it matters: It is a powerful reminder that a test can become deeply embedded in practice for legal, financial, or cultural reasons even when the clinical value is less clear than many assume.

Scholarly References on Persistent High LDL

1. Primary Clinical Guidelines

Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., ... & Wilkins, J. T. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, S0735-1097.

Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., ... & Stone, N. J. (2021). 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 78(9), 960-993.

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Belanger, M. J., ... & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), e285-e350.

2. Endocrine & Metabolic Drivers

Hypothyroidism: Rizos, C. V., Elisaf, M. S., & Liberopoulos, E. N. (2011). Effects of thyroid dysfunction on lipid profile. The Open Cardiovascular Medicine Journal, 5, 76–84.

Insulin Resistance & Particle Size: Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Després, J. P. (1997). Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation, 95(1), 69-75.

3. Renal & Hepatic Causes

Chronic Kidney Disease: Vaziri, N. D. (2006). Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. American Journal of Physiology-Renal Physiology, 290(2), F262-F272.

Biliary Obstruction (Lipoprotein X): Heimerl, S., Boettcher, A., Kaul, H., & Liebisch, G. (2016). Lipid profiling of lipoprotein X: implications for dyslipidemia in cholestasis. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1861(8), 681-687.

4. Dietary & Weight Dynamics

The Weight Loss Paradox: Phinney, S. D., Tang, A. B., Waggoner, C. R., Tezanos-Pinto, R. G., & Davis, P. A. (1991). The transient hypercholesterolemia of major weight loss. The American journal of clinical nutrition, 53(6), 1404-1410.

Lean Mass Hyper-Responders (Keto): Norwitz, N. G., Feldman, D., Soto-Mota, A., Kalayjian, T., & Ludwig, D. S. (2022). Elevated LDL cholesterol with a carbohydrate-restricted diet: evidence for a “lean mass hyper-responder” phenotype. Current Developments in Nutrition, 6(1), nzab144.

5. Physiological Transitions

Pregnancy: Piechota, W., & Staszewski, A. (1992). Reference ranges of lipids and apolipoproteins in pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology, 45(1), 27-35.

Menopause: Matthews, K. A., Crawford, S. L., Chae, C. U., Everson-Rose, S. A., Sowers, M. F., Sternfeld, B., & Sutton-Tyrrell, K. (2009). Are changes in cardiovascular disease risk factors in midlife women due to aging or the menopausal transition? Journal of the American College of Cardiology, 54(25), 2366-2373.

6. Iatrogenic (Medication-Induced)

Antipsychotics: Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Johannesen, J. K., & Lieberman, J. A. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Baseline associations with antipsychotic use. Schizophrenia Research, 101(1-3), 273-286.

Glucocorticoids: Quinkler, M., Ekman, B., Marelli, C., Uddin, S., & Zelissen, P. (2017). Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocrine, 6, 1-8.

**

This newsletter is for educational and informational purposes only and should not be considered personal medical advice. Always consult your physician or a qualified healthcare professional before making changes to your medications, diet, supplements, exercise, or health routine. Reading this content does not create a physician–patient relationship with Dr. Haque.